Found: 1

Select item for more details and to access through your institution.

  • Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab.

    Published in:
    NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00679-7
    By:
    • Lin, Douglas I.;
    • Quintanilha, Julia C. F.;
    • Danziger, Natalie;
    • Lang, Lixin;
    • Levitan, Diane;
    • Hayne, Cynthia;
    • Hiemenz, Matthew C.;
    • Smith, David L.;
    • Albacker, Lee A.;
    • Leibowitz, Jeffrey;
    • Mata, Douglas A.;
    • Decker, Brennan;
    • Lakis, Sotirios;
    • Patel, Nimesh R.;
    • Graf, Ryon P.;
    • Elvin, Julia A.;
    • Ross, Jeffrey S.;
    • Pattani, Varun;
    • Huang, Richard S. P.;
    • Wehn, Amy K.
    Publication type:
    Article